patient and scenario
In XTEND-1 and XTEND-
Kids, people taking
Zero serious allergic reactions
Although no inhibitors were found, and no serious allergic reactions occurred in clinical studies,
inhibitors and serious allergic reactions are possible with ALTUVIIIO.
In 159 people taking ALTUVIIIO in the XTEND-1 study:
- 21% of people had headache (33 people)
- 16% of people had joint pain (26 people)
- 6% of people had back pain
In 67 children taking ALTUVIIIO in the ongoing XTEND-Kids study:
- 1% of children had headache (1 child)
How does ALTUVIIIO fit into your lifestyle?
ALTUVIIIO is the only therapy of its kind that is injected once a week.
Connect With a CoRe Manager
Sanofi Hemophilia Community Relations and Education (CoRe) Managers offer education to people living with hemophilia and their families. CoRe Managers provide information about living with hemophilia and treatment options. Use our handy CoRe Locator to find the CoRe team member nearest you.
Get Informed. Stay Informed.
Let’s stay in touch. We’ll occasionally send you important information on hemophilia A and ALTUVIIIO.